Nearly 100 billion mental illness market, domestic pharmaceutical companies are expected to rely on the price advantage of "share"

At present, mental health has become a health problem that needs to be paid more and more attention to by the world.
that nearly 1 billion people worldwide are affected by varying degrees of mental health problems, but only a few have access to quality counselling and treatment.
in addition to relatively high levels of awareness of depression, there are more than 350 million people with depression worldwide, up about 18 percent in the past decade, according to the World Health Organization in 2019.
According to a 2019 article published in The Lancet Psychiatry, "The lifetime prevalence of depression in China is 6.9 percent", it can be estimated that there are currently more than 95 million people with depression in China, and the number is growing.
experts pointed out that the current domestic and foreign research and treatment of mental illness is very limited, and drugs can temporarily alleviate mental illness, such as sleep disorders, sensitivity and other symptoms.
the size of the global pharmaceutical market, psycho-neurologic drugs market after cardiovascular drugs, has become the world's second largest drug use.
china's domestic antidepressant market prospects are attracting pharmaceutical companies to accelerate the layout of the Mienet data show that in 2019 China's urban public medical institutions market in the total sales of psychosysurmic drugs reached 77.4 billion.
with the promotion of the "Healthy China" strategy, as well as the change of the society's understanding of depression and the concept of medical treatment, the industry believes that the domestic demand for antidepressants is expected to grow, and there is a lot of room for market development.
targeting a sizeable market, domestic pharmaceutical companies are accelerating towards the psycho-neural field layout.
that in recent years, there have been ZhengdaQing, Haizheng Pharmaceuticals, Howson Pharmaceuticals and Yangzijiang and other pharmaceutical companies have declared schizophrenia generic drugs on the market.
this year, there have also been a number of pharmaceutical companies out of the drug declaration of new progress.
For example, Jingxin Pharmaceuticals has announced that JX11502MA capsules, the company's innovative drug for the treatment of adult schizophrenia, have been approved for clinical trials, after Yangzijiang Pharmaceuticals announced that Nanjing Hailing Pharmaceuticals' generic drug for adult schizophrenia, Lulaxi ketone tablets, has been approved for sale.
statistics, as of August 11, the domestic neurological drugs have a class 1 new drugs and 41 generic drug market applications in the review and approval.
Among them, in addition to focusing on the spirit, anesthesiology drugs, People's Fu Pharmaceuticals, Enhua Pharmaceuticals, Haizheng Pharmaceuticals, Zhengda Tianqing, Howson Pharmaceuticals and other pharmaceutical companies that were not involved in this field also began to lay out.
domestic enterprises mainly to generic drugs is expected to open the market by virtue of price advantage, then, the current domestic nervous system drug market pattern? According to the sales pattern of the top ten manufacturers of terminal neurological drugs in China's public medical institutions in 2019, most of them are mainly domestic enterprises, accounting for 80% and the other two are owned by two foreign investors, Lingbei and Bayer.
it is worth mentioning that in these 80% of domestic enterprises, mainly generic drugs.
in terms of price, these over-evaluated drugs will be better than imported drugs, with the national and local harvesting and health insurance policies, the expected low prices, clear efficacy of drugs in the domestic or have a larger market.
present, the results of the third batch of national selection has been announced, Taiji Group holding subsidiary Southwest Pharmaceuticals has been evaluated for the "brominate citopram tablets" to select this collection.
, the hydrobrominate sitrapland tablet is an adaptation to the treatment of depression and is a Class B drug in the 2019 edition of the health insurance catalog.
Taiji Group said that the company's 2019 sales revenue of 2.97 million yuan, accounting for 0.03 percent of the company's sales revenue for the year.
this drug collection as confirmed winning bid, in the procurement cycle, medical institutions will give priority to use and ensure the completion of the agreed procurement volume.
Koren Pharmaceuticals disclosed in the Chinese newspaper, the company currently has a total of 10 products, includingacid tofatin cloth tablets, hydrobrominate citriciprin tablets / capsules, hydrochloric acid dapositin tablets, hertic acid Essiupram tablets, including 10 products, 12 specifications into one to three batches of national mining.
among them, the grass acid Esciopram tablets (Belot) with the policy advantages of the second round of expansion of the volume procurement and the academic promotion model of the direct-camp team bucked the trend, the first half of the sales volume increased by 6.21% YoY.
the industry believe that with the accelerated development of the large health industry, Chinese medicine antidepressants may be expected to become the new favorite of health insurance.
For example, Bei lu pharmaceutical company, which is committed to building an anti-anxiety Brand, achieved rapid growth in 2019 with sales of 68 million pure Chinese medicine products approved for the treatment of widespread anxiety disorders, up 59.96 percent year-on-year.
, the product has been the winning bid in more than 20 provinces, Shanxi, Beijing can be reimbursed for medical insurance.
of income, Shanxi and Beijing basically account for half of total income, the role of health care is obvious.
Overall, the domestic psycho-drug market prospects are considerable, but the market competition is particularly fierce, coupled with such drugs face strict control policies, small and medium-sized enterprises may be difficult to obtain opportunities, and the giant is expected to rely on its technology, capital advantages "share."
under the influence of future policy orientation and drug demand, the types of psychotic drugs in China are more abundant, and pharmaceutical companies will enhance their competitiveness by expanding drug adaptation and efficacy.
The industry believes that in the short term, psycho-drugs will still be generic-based to meet the growing demand for domestic drug use, and in the long run, there will be the emergence of improved new drugs, drug dosage forms will develop to long-acting preparations, reduce the number of drug use at the same time improve the effectiveness of drug use.